atorvastatin xiromed 10 mg filmdragerad tablett
medical valley invest ab - atorvastatinkalciumtrihydrat - filmdragerad tablett - 10 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; atorvastatinkalciumtrihydrat 10,85 mg aktiv substans
atorvastatin xiromed 20 mg filmdragerad tablett
medical valley invest ab - atorvastatinkalciumtrihydrat - filmdragerad tablett - 20 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; atorvastatinkalciumtrihydrat 21,7 mg aktiv substans
atorvastatin xiromed 80 mg filmdragerad tablett
medical valley invest ab - atorvastatinkalciumtrihydrat - filmdragerad tablett - 80 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; atorvastatinkalciumtrihydrat 86,8 mg aktiv substans
quiflox vet 20 mg tablett
krka d.d., novo mesto - marbofloxacin - tablett - 20 mg - laktosmonohydrat hjälpämne; marbofloxacin 20 mg aktiv substans - marbofloxacin - hund
quiflox vet 5 mg tablett
krka d.d., novo mesto - marbofloxacin - tablett - 5 mg - marbofloxacin 5 mg aktiv substans; laktosmonohydrat hjälpämne - marbofloxacin - hund, katt
quiflox vet 80 mg tablett
krka d.d., novo mesto - marbofloxacin - tablett - 80 mg - laktosmonohydrat hjälpämne; marbofloxacin 80 mg aktiv substans - marbofloxacin - hund
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
letybo 50 enheter pulver till injektionsvätska, lösning
croma-pharma gmbh - clostridium botulinum typ a neurotoxin - pulver till injektionsvätska, lösning - 50 enheter - clostridium botulinum typ a neurotoxin 50 e aktiv substans
talvey
janssen-cilag international n.v. - talquetamab - multipelt myelom - antineoplastiska medel - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
ciprofloxacin fresenius kabi 2 mg/ml infusionsvätska, lösning
fresenius kabi ab - ciprofloxacinvätesulfat - infusionsvätska, lösning - 2 mg/ml - ciprofloxacinvätesulfat 2,6 mg aktiv substans - ciprofloxacin